CorMedix Inc.

NasdaqGM:CRMD 株式レポート

時価総額：US$571.5m

CorMedix マネジメント

マネジメント 基準チェック /44

CorMedixの CEO はJoe Todiscoで、 May2022年に任命され、 の在任期間は 3.92年です。 の年間総報酬は$ 2.36Mで、 27.1%給与と72.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.51%を直接所有しており、その価値は$ 2.90M 。経営陣と取締役会の平均在任期間はそれぞれ2.2年と4.1年です。

主要情報

Joe Todisco

最高経営責任者

US$2.4m

報酬総額

CEO給与比率27.09%
CEO在任期間3.9yrs
CEOの所有権0.5%
経営陣の平均在職期間2.2yrs
取締役会の平均在任期間4.1yrs

経営陣の近況

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade)

Apr 02

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.

CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%

Feb 06
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%

CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors

Dec 23
CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors

Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position

Aug 14
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position

It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD)

Aug 09
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD)

Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Jun 27
Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
User avatar

DefenCath Launch Will Boost Inpatient And Dialysis Opportunities

Strong revenue growth prospects from DefenCath's successful launch and expansion into new segments like inpatient facilities and partnerships.

The Hidden Risks Behind CorMedix's First Profitable Quarter

Mar 26

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jan 17
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix: Finally In Commercialization Mode

Jan 07

CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Dec 13
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

CEO報酬分析

CorMedix の収益と比較して、Joe Todisco の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2025n/an/a

US$162m

Sep 30 2025n/an/a

US$162m

Jun 30 2025n/an/a

US$51m

Mar 31 2025n/an/a

US$17m

Dec 31 2024US$2mUS$639k

-US$18m

Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$617k

-US$46m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$3mUS$378k

-US$30m

報酬と市場: Joeの 総報酬 ($USD 2.36M ) は、 US市場 ($USD 2.40M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Joeの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Joe Todisco (49 yo)

3.9yrs
在職期間
US$2,359,909
報酬

Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022 and is its Chairman of the Board of Directors from January, 2026. He is a Director of Talph...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Joseph Todisco
CEO & Chairman of the Board of Directors3.9yrsUS$2.36m0.51%
$ 2.9m
Elizabeth Masson-Hurlburt
Executive VP2.2yrsUS$1.14m0.081%
$ 464.6k
Matthew David
EVP & Chief Business Officerless than a yearUS$1.09m0.034%
$ 195.7k
Susan Blum
EVP & Chief Financial Officerless than a yearデータなし0.011%
$ 61.0k
Kaufman Zelnick
EVP, Chief Legal and Compliance Officer & Corporate Secretary2.3yrsデータなし0.14%
$ 793.4k
Beth Steinbrenner
SVP & Chief Human Resource Officerless than a yearデータなしデータなし
Donna Ucci
Senior VP & Head of Global Quality3.9yrsデータなしデータなし
Tushar Mukherjee
Senior VP & Head of Technical Operations3.3yrsデータなしデータなし
Michael Seckler
EVP & Chief Commercial Officerless than a yearデータなしデータなし
Peter Sullivan
Senior Vice President of Market Accessno dataデータなしデータなし
Jared Crandon
Executive Director of Clinical Portfolio Managementno dataデータなしデータなし
2.2yrs
平均在職期間
50.5yo
平均年齢

経験豊富な経営陣: CRMDの経営陣は 経験豊富 であると考えられます ( 2.2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Joseph Todisco
CEO & Chairman of the Board of Directors4.1yrsUS$2.36m0.51%
$ 2.9m
Myron Kaplan
Lead Independent Director10yrsUS$210.56k0.29%
$ 1.7m
Alan Dunton
Independent Director7.1yrsUS$153.56k0.051%
$ 291.0k
Janet Dillione
Independent Director10.7yrsUS$159.56k0.049%
$ 278.2k
Steven Lefkowitz
Independent Director8.8yrsUS$174.56k0.12%
$ 704.9k
Gregory Duncan
Independent Director5.4yrsUS$153.56k0.048%
$ 277.1k
Bruce Polsky
Member of Scientific Advisor Boardno dataデータなしデータなし
Saravanan Balamuthusamy
Member of Scientific Advisory Board4yrsデータなしデータなし
Sara Bonnes
Member of Scientific Advisory Board4yrsデータなしデータなし
Aru Narendran
Member of Scientific Advisory Board4yrsデータなしデータなし
Hannah Newman
Member of Scientific Advisory Board4yrsデータなしデータなし
Jonathan Waitman
Member of Scientific Advisory Board4yrsデータなしデータなし
4.1yrs
平均在職期間
69yo
平均年齢

経験豊富なボード: CRMDの 取締役会 は 経験豊富 であると考えられます ( 4.1年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/04/09 19:02
終値2026/04/09 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

CorMedix Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
Andrew D'SilvaB. Riley Securities, Inc.
Jason ButlerCitizens JMP Securities, LLC
Jason KolbertD. Boral Capital LLC.